|
|
|
|
|
|
|
|
|
|
|
04.09.25 - 17:33
|
Biocodex Invests up to €30 Million in MRM Health, a Belgian Microbiome Therapy Innovator (Business Wire)
|
|
|
GENTILLY, France--(BUSINESS WIRE)--Biocodex, a French family-owned pharmaceutical pioneer in microbiota research for over 70 years, announces a strategic equity investment of €11 million in MRM Health, a Belgian clinical-stage biotech developing innovative microbiome-based therapeutics for inflammatory diseases and immune-oncology. The total partnership could reach approximately €30 million, reflecting Biocodex's long-term commitment to advancing new therapeutic approaches.
MRM Health's €55 million Series B round was led by Biocodex, with strong participation from ATHOS, new investor BNP Paribas Fortis Private Equity, and existing investors SFPIM (Belgium's sovereign wealth fund), Ackermans & van Haaren (AvH), OMX Ventures Europe (OMX), and Qbic II.
MRM Health is developing innovative treatments based on the human microbiome to address major diseases such as Inflammatory Bowel Diseases, autoimmune disorders, and certain cancers. Its lead asset, the flagship molecule MH002, has completed successfu...
|
|
|
|
|
04.09.25 - 07:06
|
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline (Business Wire)
|
|
|
Funding to support Phase 2b trial with MRM Health's lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Strategic partnership with Biocodex in biotherapeutics development and manufacturing adds significant non-dilutive funding in addition to the Series B financing
Investment fuels expansion of proprietary CORAL® platform and pipeline
GHENT, Belgium--(BUSINESS WIRE)--#Parkinson--MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round.
The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB.
Validation of Leadership Position in Microbiome-Based Therapeutics
...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.11.24 - 07:44
|
Ackermans & Van Haaren On Track For FY Net Profit Above EUR 400 Mln (Reuters EN)
|
|
|
BRIEF-Ackermans & Van Haaren On Track For FY Net Profit Above EUR 400 Mln Nov 22 (Reuters) - Ackermans & Van Haaren NV ACKB.BR : ON TRACK TOWARDS NET PROFIT FOR FY 2024 THAT IS WELL ABOVE 400 MILLION EUROS MAINTAINS END-SEPT ROBUST NET CASH POSITION OF 294.8 MILLION EUROS Source text: ID:nGNE6dZF8K Further company coverage: ACKB.BR (Gdansk Newsroom...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
